Sanofi's Covid-19 vaccine candidate, which is modelled on the virus's Beta antigen, delivered 72 per cent efficacy in adults against the Omicron strain, the French drugmaker said on Friday, citing data gathered in a study.
"Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," the firm, which is developing the vaccine jointly with Britain's GSK, said in a statement, reports Reuters.
The new data supporting its booster vaccine will be submitted to regulatory authorities, Sanofi added, reiterating its plan to start marketing its jab later this year.